Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

IMI delivers record profits in FY24

(Sharecast News) - Engineering firm IMI delivered record profits in FY24, thanks to "good organic growth" and "strong cash generation". IMI said on Friday that full-year revenues had grown 1% to £2.21bn, partly driven by "good demand" for its energy-saving climate control solutions, while operating margins improved by 100 basis points to 19.7% as margins improved in both of its platforms, reflecting strategic execution and strong pricing power.

As a result, pre-tax profits were up 8% to an all-time high of £419.0m and basic earnings per share increased 5% to 122.5p.

IMI recommended a final dividend of 21.1p per share and also said it would now launch a share buyback to repurchase a further £200.0m ordinary shares.

Looking forward, IMI said it expects FY25 to mark "another year of strong financial and strategic progress", with FY adjusted EPS pegged to be between 129.0p and 136.0p.

"We expect to deliver continued margin progression in 2025, supported by further growth and the final benefits from the complexity reduction programme. We will continue to identify and execute efficiencies to drive improvements, with any future restructuring charges for our current business taken into underlying operating profit," said IMI.

As of 0845 GMT, IMI shares were up 3.38% at 1,956.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.